Glenmark Generics Inc, USA, the US subsidiary of Glenmark Generics Ltd, has announced the settlement of litigation pending between Glenmark and Janssen Pharmaceuticals over patent actions concerning Norgestimate and Ethinyl Estradiol tablets. The latter comprises the generic version of Janssen Ortho Tri-cyclen Lo tablets.
Under the terms of the settlement agreements, Glenmark will be able to market and distribute its Norgestimate and Ethinyl Estradiol tablets under a royalty-bearing licence from Janssen on December 31, 2015, or earlier under certain circumstances.
Janssen currently markets its product as Ortho Tri-cyclen Lo in the US, indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Total US sales as reported by IMS Health for the 12-month period ending June 2012 were approximately $397 million.
Keywords: Glenmark Generics Inc, USA, settles litigation in US, litigation involving Glenmark, Janssen Pharmaceuticals on patent actions, Glenmark litigation over Norgestimate, Ethinyl Estradiol tablets